J&J announced the FDA jas granted the investigational drug, nipocalimab (FcRn recpt Ab), with Fast Track designation for its study in adult patients with moderate-to-severe Sjögren’s disease https://t.co/TB2cESMLQi https://t.co/IC7PQP2fcx
Links:
Nipocalimab, the first and only investigational treatment to be granted U.S. FD…
https://buff.ly/SFYky98
Mar-20-2025
